Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by sah1on Jul 25, 2017 12:37pm
249 Views
Post# 26506485

RE:RE:Reading the PG deficiency FB page---posters are as

RE:RE:Reading the PG deficiency FB page---posters are asStag, are you really expecting PLI to sign a deal on Pg for congenital deficiency? I certainly am not. Perhaps for wound caring (i.e. diabetic ulcers) but only after we get results from the Swedish trials. For me, partnerships  and deals in the short term are most likely related to 4050, either more deals like SRAM or deals on specific apps of 4050 for specific geographic territories e.g. IPF for Europe).


Bullboard Posts